The new patent covers DNA vaccines containing codon-optimized versions of genes encoding gB and CMV phosphoprotein 65 (pp65) antigens, and adds to Vical‘s family of patents in the US and other key regions.
Vical has additional issued patents that cover the composition and use of its Vaxfectin adjuvant.
Currently, Vical is developing TransVax, a therapeutic DNA vaccine encoding the CMV gB and the pp65 antigens formulated with a poloxamer which enhances a cellular immune response.
The TransVax vaccine has orphan drug designation for transplant patients, and the company expects to begin Phase 3 trials for it in the second half of 2011.
Vical is also developing CyMVectin, a prophylactic DNA vaccine designed to enhance both antibody and T-cell responses to prevent infection in females of child-bearing potential.
The US Food and Drug Administration has granted Vical the investigational new drug application for a Phase 1 trial of CyMVectin vaccine, and the company is exploring collaborative opportunities for future development and commercialization.